Full Text
Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study

Abstract

Authors

N Paracha F Felizzi

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×